NASDAQ:XDNA Kelly CRISPR & Gene Editing Technology ETF (XDNA) Price, Holdings, & News → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free XDNA Stock Alerts $7.38 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$7.38▼$7.3850-Day Range$7.38▼$7.3852-Week Range$5.87▼$11.83VolumeN/AAverage Volume3,034 shsMarket Capitalization$2.21 millionAssets Under Management$2.58 millionDividend Yield0.12%Net Expense Ratio0.78% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOptions ChainRatingsShort InterestSocial MediaStock AnalysisChartHeadlinesHoldingsOptions ChainRatingsShort InterestSocial Media Get Kelly CRISPR & Gene Editing Technology ETF alerts: Email Address About Kelly CRISPR & Gene Editing Technology ETF (NASDAQ:XDNA)The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly.Read More XDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XDNA ETF News HeadlinesMarch 9, 2024 | markets.businessinsider.comCRISPR Technology Takes Center Stage at SXSW 2024 for the First TimeFebruary 15, 2024 | markets.businessinsider.comIntellia Collaborates With ReCode To Develop Gene Therapy For Cystic FibrosisApril 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.January 15, 2024 | msn.comHere's Why CRISPR Therapeutics Stock Rose 54% Last YearDecember 8, 2023 | news.yahoo.comGene editing is now a medical realityDecember 8, 2023 | news.yahoo.comFDA approves first use of CRISPR gene editing to treat sickle cell diseaseDecember 8, 2023 | markets.businessinsider.comFDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood DisorderNovember 24, 2023 | msn.comGene Editing Will Change Medicine—and Maybe Health Investing TooApril 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.November 22, 2023 | msn.comIs CRISPR Therapeutics the Best Gene-Editing Stock?See More Headlines Receive XDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kelly CRISPR & Gene Editing Technology ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerKelly Strategic Management Fund NameKelly CRISPR & Gene Editing Technology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:XDNA Inception Date1/12/2022 Fund ManagerDustin Lewellyn, Ernesto Tong, Anand Desai WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkStrategic CRISPR & Gene Editing Technology Index CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings2 Fund Statistics Assets Under Management$2.58 million Average Daily Volume$0.00 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorKelly Strategic Management, LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerJane Street Miscellaneous Outstanding Shares300,000Beta0.92 Creation Unit25,000 Creation Fee$250.00 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Kelly CRISPR & Gene Editing Technology ETF ExpensesTypeXDNATheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.78%0.57%0.54%0.48%0.51%Other Expenses0.00%0.72%0.54%0.34%0.58%Total Expense0.78%0.72%0.70%0.58%0.70%Fee Waiver0.00%-0.76%-0.54%-0.22%-0.57%Net Expense0.78%0.59%0.60%0.54%0.58% Kelly CRISPR & Gene Editing Technology ETF (XDNA) HoldingsTop 10 XDNA HoldingsIntellia Therapeutics(NASDAQ:NTLA)Holding Weight: 11.05%Thermo Fisher Scientific(NYSE:TMO)Holding Weight: 10.70%Beam Therapeutics(NASDAQ:BEAM)Holding Weight: 9.57%CRISPR Therapeutics(NASDAQ:CRSP)Holding Weight: 8.64%Caribou Biosciences(NASDAQ:CRBU)Holding Weight: 6.78%Verve Therapeutics(NASDAQ:VERV)Holding Weight: 5.63%Sangamo Therapeutics(NASDAQ:SGMO)Holding Weight: 5.16%Prime Medicine(NYSE:PRME)Holding Weight: 4.73%AbbVie(NYSE:ABBV)Holding Weight: 4.37%Editas Medicine(NASDAQ:EDIT)Holding Weight: 4.13%Full Holdings Details Similar ETFsGlobal X Emerging Markets Internet & E-commerce ETFNASDAQ:EWEBProcure Disaster Recovery Strategy ETFNASDAQ:FIXTGlobal X Education ETFNASDAQ:EDUTGlobal X Wind Energy ETFNASDAQ:WNDYGlobal X PropTech ETFNASDAQ:PTEC XDNA ETF - Frequently Asked Questions How have XDNA shares performed in 2024? Kelly CRISPR & Gene Editing Technology ETF's stock was trading at $7.38 at the beginning of 2024. Since then, XDNA shares have increased by 0.0% and is now trading at $7.38. View the best growth stocks for 2024 here. What does XDNA invest in? Kelly CRISPR & Gene Editing Technology ETF is a equity fund issued by Kelly Strategic Management. XDNA focuses on theme investments and follows the Strategic CRISPR & Gene Editing Technology Index. The fund's investments total to approximately $2.58 million assets under management. What stocks does Kelly CRISPR & Gene Editing Technology ETF hold? XDNA invests in 2 holdings. Some of the stocks in their portfolio include Intellia Therapeutics (NTLA), Thermo Fisher Scientific (TMO), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Caribou Biosciences (CRBU), Verve Therapeutics (VERV), Sangamo Therapeutics (SGMO), Prime Medicine (PRME), AbbVie (ABBV) and Editas Medicine (EDIT). What is the management fee for Kelly CRISPR & Gene Editing Technology ETF? Kelly CRISPR & Gene Editing Technology ETF's management fee is 0.78% and has no other recorded expenses or fee waivers. The net expense ratio for XDNA is 0.78%. How do I buy shares of Kelly CRISPR & Gene Editing Technology ETF? Shares of XDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XDNA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
